GIDEON KOREN, M.D.
Osteopathic Medicine at Hoppin St, Providence, RI
License number
Rhode Island 59321
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
2
1 Hoppin St, Providence, RI 02903
64 Blake Rd, Brookline, MA 02445
64 Blake Rd, Brookline, MA 02445
Phone
(401) 444-4629
Personal information
See more information about GIDEON KOREN at radaris.comName
Address
Phone
64 Blake Rd, Brookline, MA 02445
64 Blake Rd, Brookline, MA 02445
64 Blake Rd, Brookline, MA 02445
Organization information
See more information about GIDEON KOREN at bizstanding.comGideon Koren MD
1 Hoppin St, Providence, RI 02903
Industry:
Internist
Phone:
(401) 444-4629 (Phone)
Gideon Koren
Professional information
See more information about GIDEON KOREN at trustoria.com
Dr. Gideon Koren, Providence RI - MD (Doctor of Medicine)
Dr. Gideon Koren, Providence RI - MD (Doctor of Medicine)
Specialties:
Cardiology
Address:
1 Hoppin St SUITE 5103, Providence 02903
(401) 444-4629 (Phone)
RHODE ISLAND HOSPITAL
1 Hoppin St, Providence 02903
(401) 793-8560 (Phone), (401) 444-7397 (Fax)
(401) 444-4629 (Phone)
RHODE ISLAND HOSPITAL
1 Hoppin St, Providence 02903
(401) 793-8560 (Phone), (401) 444-7397 (Fax)
Languages:
English
Education:
Medical School
The Hebrew University / Hadassah Medical School
The Hebrew University / Hadassah Medical School
Gideon Koren, Providence RI
Gideon Koren, Providence RI
Specialties:
Cardiologist
Address:
1 Hoppin St, Providence, RI 02903
Animal Models Of Long Qt Syndrome And Uses Thereof
Animal Models Of Long Qt Syndrome And Uses Thereof
US Patent:
2006025, Nov 16, 2006
Filed:
May 16, 2005
Appl. No.:
11/130031
Inventors:
Gideon Koren - Brookline MA, US
Xuwen Peng - Hershey PA, US
Rajesh Mathur - Vancover, CA
Manfred Zehender - Freiburg, DE
Xuwen Peng - Hershey PA, US
Rajesh Mathur - Vancover, CA
Manfred Zehender - Freiburg, DE
International Classification:
A01K 67/027, C40B 30/02
US Classification:
800014000, 435007100
Abstract:
Provided are animal models of long QT syndrome (LQTS). The animal models are useful, for example, in screening of drugs for adverse effects in subjects with LQTS, in screening candidate therapeutics for the treatment or prevention of LQTS, and in determining gene expression in LQTS.